Company Overview
Larimar Therapeutics, Inc. operates as a clinical-stage biotechnology company dedicated to developing treatments for rare diseases through its novel cell penetrating peptide technology platform. The company is situated within the healthcare sector, specifically focusing on the biotechnology industry, which involves high-risk research and development activities aimed at creating novel therapies for unmet medical needs. As of the latest available data, the organization employs 71 individuals and holds a market capitalization of $486.17M, while its annual revenue is not publicly disclosed in standard financial reports. The market cap of $486.17M indicates that the market values the company's potential pipeline assets and proprietary technology significantly, even though the lack of reported annual revenue suggests the company is currently in a capital-intensive development phase where expenditures on research exceed immediate sales generation.
Financial Health
The company reports a net income of $-165,672,992 and an EBITDA of $-172,147,008 over the trailing twelve-month period, with free cash flow standing at $-53,473,624. The substantial gap between the reported net income and EBITDA reveals a significant impact from non-operating expenses or specific accounting adjustments, though the primary driver of the negative figures is the inherent cost structure of a clinical-stage biotechnology firm investing heavily in trial operations. Free cash flow is negative at $-53,473,624, which indicates that the company is burning cash to fund its operations and clinical trials, relying on external capital sources to maintain financial flexibility until product approval and commercialization occur. All three margin metrics—gross margin, operating margin, and profit margin—are recorded at 0.0%, a figure typical for early-stage biotech entities that have not yet achieved commercial product sales, reflecting that costs are incurred without corresponding revenue recognition. The company holds $136.85M in cash against $4.07M in debt, resulting in a debt-to-equity ratio of 5.21, which suggests a balance sheet that is leveraged relative to equity but possesses substantial liquid assets to cover obligations. A current ratio of 2.19 demonstrates strong short-term liquidity, indicating that the company holds more than twice the current assets necessary to meet its short-term liabilities without immediate distress. Return on Equity stands at -132.6% and return on assets is -62.3%, metrics that reveal management is utilizing shareholder capital and assets to generate losses rather than profits, a common characteristic during the pre-revenue clinical development stage of a biotechnology company.
Valuation Assessment
The trailing twelve-month P/E ratio is listed as N/A due to the absence of earnings, while the forward P/E is calculated at -2.60, a valuation metric that implies negative expected earnings in the near term. The price-to-book ratio is 4.98, indicating that the market values the company at nearly five times its book value, which suggests investors are pricing in significant future potential from the lead product candidate CTI-1601 despite current losses. Alternative valuation metrics include a price-to-sales ratio of N/A and an EV/EBITDA of -2.05, figures that suggest the market is valuing the firm based on asset backing and potential rather than current cash flow generation or sales multiples. The stock has traded between a 52-week low of $1.61 and a 52-week high of $6.42, meaning the current trading price fluctuates within a range that reflects the high volatility associated with clinical-stage biotechnology equities. The beta value of 0.96 indicates that the stock's price volatility is roughly equivalent to the broader market, suggesting it does not exhibit extreme sensitivity to general market movements compared to smaller-cap peers with higher betas.
Growth & Income
Revenue growth year-over-year and earnings growth year-over-year are both listed as N/A, reflecting the company's status as a pre-revenue entity where traditional growth metrics have not yet materialized. Consequently, the company does not pay dividends, as evidenced by a dividend yield of N/A and a payout ratio of 0.0%, meaning all available earnings and cash reserves are reinvested into research and development rather than distributed to shareholders. Since the company has not generated positive earnings to support a dividend program, the absence of a payout ratio is consistent with the strategy of funding growth through operational reinvestment and external financing. The overall growth and income profile for Larimar Therapeutics is defined by capital deployment into its Phase 2 OLE clinical trial for Friedreich's ataxia rather than current financial returns or shareholder distributions.